肝硬化合并细菌和真菌感染患者经验性抗生素治疗临床反应的决定因素——来自国际腹水俱乐部「全球研究」的结果
该前瞻性队列纳入46个中心1302例肝硬化合并细菌或真菌感染的住院患者,仅61%对经验性抗生素治疗产生临床反应。C反应蛋白、血白细胞计数、血清白蛋白、医院获得性感染、肺炎及药敏试验提示治疗无效是缺乏临床反应的独立预测因素;临床反应是28天生存的独立预测因素。
要点
- 肝硬化合并细菌或真菌感染患者中仅61%对经验性抗生素治疗有临床反应。
- 药敏试验提示治疗无效者缺乏临床反应的OR为5.32(95%CI 3.47-8.57)。
- 无临床反应者感染消散率55% vs 有反应者96%(p<0.001)。
核心结论
- 约四成肝硬化合并细菌或真菌感染患者对一线抗生素治疗无临床反应,导致感染消散率更低、死亡率更高。
- 作者认为,对高炎症状态、低血清白蛋白及严重肝损伤患者,广谱抗生素及针对系统性炎症的策略可能改善预后。
研究设计与样本
- 国际腹水俱乐部「全球研究」前瞻性队列,2015年10月至2016年9月在46个中心纳入1302例肝硬化合并细菌或真菌感染的住院患者。
- 临床反应根据感染或炎症标志物变化、生命体征、器官衰竭改善及培养结果定义。
主要发现
- 仅61%的病例对经验性抗生素治疗产生临床反应。
- 缺乏临床反应的独立预测因素包括:C反应蛋白(OR=1.16;95%CI=1.02-1.31)、血白细胞计数(OR=1.39;95%CI=1.09-1.77)、血清白蛋白(OR=0.70;95%CI=0.55-0.88)、医院获得性感染(OR=1.96;95%CI=1.20-2.38)、肺炎(OR=1.75;95%CI=1.22-2.53)及药敏试验提示治疗无效(OR=5.32;95%CI=3.47-8.57)。
- 与有临床反应者相比,对一线抗生素治疗无临床反应者的感染消散率更低(55% vs 96%;p<0.001)、二次感染发生率更高(29% vs 15%;p<0.001)、休克发生率更高(35% vs 7%;p<0.001)、新发器官衰竭发生率更高(52% vs 19%;p<0.001)。
- 临床反应是28天生存的独立预测因素(subdistribution=0.20;95%CI=0.14-0.27)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The administration of an appropriate empirical antibiotic treatment is essential in cirrhosis and severe bacterial infections. We aimed to investigate the predictors of clinical response of empirical antibiotic treatment in a prospective cohort of patients with cirrhosis and bacterial and fungal infections included in the International Club of Ascites "Global Study." METHODS: Patients hospitalized with cirrhosis and bacterial/fungal infection were prospectively enrolled at 46 centers. Clinical response to antibiotic treatment was defined according to changes in markers of infection/inflammation, vital signs, improvement of organ failure, and results of cultures. RESULTS: From October 2015 to September 2016, 1302 patients were included at 46 centers. A clinical response was achieved in only 61% of cases. Independent predictors of lack of clinical response to empirical treatment were C-reactive protein (OR = 1.16; 95% CI = 1.02-1.31), blood leukocyte count (OR = 1.39;95% CI = 1.09-1.77), serum albumin (OR = 0.70; 95% CI = 0.55-0.88), nosocomial infections (OR = 1.96; 95% CI = 1.20-2.38), pneumonia (OR = 1.75; 95% CI = 1.22-2.53), and ineffective treatment according to antibiotic susceptibility test (OR = 5.32; 95% CI = 3.47-8.57). Patients with a lack of clinical response to first-line antibiotic treatment had a significantly lower resolution rate of infections (55% vs. 96%; p < 0.001), a higher incidence of second infections (29% vs. 15%; p < 0.001), shock (35% vs. 7%; p < 0.001) and new organ failures (52% vs. 19 %; p < 0.001) than responders. Clinical response to empirical treatment was an independent predictor of 28-day survival ( subdistribution = 0.20; 95% CI = 0.14-0.27). CONCLUSIONS: Four out of 10 patients with cirrhosis do not respond to the first-line antibiotic therapy, leading to lower resolution of infections and higher mortality. Broader-spectrum antibiotics and strategies targeting systemic inflammation may improve prognosis in patients with a high degree of inflammation, low serum albumin levels, and severe liver impairment.
引用
- Maiwall R, Piano S, Singh V, et al. Determinants of clinical response to empirical antibiotic treatment in patients with cirrhosis and bacterial and fungal infections-Results from the ICA "Global Study" (EABCIR-Global Study). Hepatology. 2023. PMID: 38047909. doi:10.1097/HEP.0000000000000653
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。